At present, the immune checkpoint inhibitors used to treat advanced renal cell carcinoma, such as Keytruda and Opdivo, can enhance the immune response against renal cell carcinoma by blocking PD-1. This evidence concerns the gene PDCD1 and renal cell carcinoma.